RE: Avacta Publicity10 Jul 2024 11:37
Use 12ft to get past a pay wall.
Avacta is also striving to treat cancer more effectively, this time by making chemotherapy more targeted and less toxic for patients.
No one doubts that chemotherapy can work wonders on tumours but it has sometimes ruinous side-effects, from nausea to extreme fatigue to a savage reduction in immunity.
These occur because chemotherapy kills any cells that are dividing, whether they are healthy or not. Avacta has found a clever little protein that can be added to chemotherapy drugs so they only kill cancerous cells, leaving the rest of the body alone.
Trials are at an even earlier stage than Scancell's but they are already attracting interest from leading specialists and drug firms, because they could prove revolutionise cancer treatment worldwide.
Midas verdict: Avacta, which is also listed on AIM, has had a long and tumultuous past. In January, however, Christina Coughlin was parachuted in as chief executive and a new chairman was appointed only last month. Changes are already under way and more are expected this year.
A cancer doctor in the US for many years, Coughlin has seen the debilitating effects of chemotherapy first-hand and is keen to do everything in her power to improve patients' lives. With decades of experience in drug companies large and small, she is also well equipped to take Avacta to the next level. At 60p, the shares are worth a closer look.
Sign In
Follow the stocks
